TG
AIMT

TLP Group’s Aimmune Therapeutics AIMT Stock Holding History

TLP Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-580,000
Closed -$18.5M – 529
2018
Q1 		$18.5M Sell
580,000
-470,000
-45% -$16.5M 12.66% 1
2017
Q4 		$39.7M Sell
1,050,000
-934,476
-47% -$30.2M 27.53% 1
2017
Q3 		$49.2M Sell
1,984,476
-150,000
-7% -$3.23M 30.91% 1
2017
Q2 		$43.9M Sell
2,134,476
-100,000
-4% -$1.91M 41.01% 1
2017
Q1 		$48.6M Sell
2,234,476
-233,500
-9% -$4.79M 33.14% 1
2016
Q4 		$50.5M Sell
2,467,976
-436,209
-15% -$8.92M 50.03% 1
2016
Q3 		$43.6M Buy
2,904,185
+70,900
+3% +$957K 45.99% 1
2016
Q2 		$30.7M Buy
2,833,285
+17,000
+0.6% +$231K 20.86% 1
2016
Q1 		$38.2M Buy
2,816,285
+35,026
+1% +$546K 23.2% 1
2015
Q4 		$51.3M Buy
+2,781,259
New +$51.5M 40.87% 1

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

TLP Group's AIMT Position: Q2 2018 in Review

TLP Group sold out of Aimmune Therapeutics (AIMT) in Q2 2018, closing a stake of 580,000 shares — an estimated $18.5M sold.

TLP Group first reported a position in AIMT in Q4 2015 and held it in 10 quarters. The position peaked at $51.3M in Q4 2015. 151 funds tracked by Wall St. Rank hold AIMT as of Q2 2018.

  • TLP Group reported no remaining Aimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
  • TLP Group sold 580,000 Aimmune Therapeutics shares in Q2 2018, an estimated $18.5M.
  • TLP Group first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 10 quarters.
  • TLP Group's Aimmune Therapeutics position peaked at $51.3M in Q4 2015.
  • 151 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2018.

Based on TLP Group's 13F filing for Q2 2018, filed 14 Aug 2018.